Malin Petersson

Artiklar

Article: THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS. 2024;17:17562864241279125
Maintenance of zilucoplan efficacy in patients with generalised myasthenia gravis up to 24 weeks: a model-informed analysis
de la Borderie G; Chimits D; Boroojerdi B; Brock M; Duda PW; Grimson F; Mahoney P; Strimenopoulou F; Cutter G; Aban I; Brauner S; Petersson M; Howard Jr JF; Bennett N
Article: NEUROLOGY. 2021;97(14):e1382-e1391
Patient-Reported Symptom Severity in a Nationwide Myasthenia Gravis Cohort Cross-sectional Analysis of the Swedish GEMG Study
Petersson M; Feresiadou A; Jons D; Ilinca A; Lundin F; Johansson R; Budzianowska A; Roos A-K; Kagstrom V; Gunnarsson M; Sundstrom P; Piehl F; Brauner S

Conference publication: EUROPEAN JOURNAL OF NEUROLOGY. 2023;30:477
Correlation of disease activity and EQ-5D-3L-derived utility in myasthenia gravis patients in a Swedish national cohort
Petersson M; Berggren F; Lindberg I; Piehl F; Brauner S
Conference publication: EUROPEAN JOURNAL OF NEUROLOGY. 2023;30:54-55
Smoking and alcohol associated to the risk of developing Myasthenia gravis in a Swedish nationwide prevalent cohort
Petersson M; Jons D; Feresiadou A; Ilinca A; Lundin F; Johansson R; Budzianowska A; Roos A; Kagstrom V; Gunnarsson M; Sundstrom P; Klareskog L; Olsson T; Kockum I; Piehl F; Alfredsson L; Brauner S